'An exciting new period for AstraZeneca': Drugs giant's shares launch on New York Stock Exchange

Drugs giant AstraZeneca has listed on the New York Stock Exchange, as it targets further global growth.

The UK based-pharmaceutical giant is transitioning to the market by delisting American Depositary Shares from the Nasdaq index.

AstraZeneca started trading on the NYSE on Monday after it stopped trading ADS and certain debt securities on the Nasdaq after the end of trading on Friday.

The FTSE 100 firm will maintain its listings on the London Stock Exchange and Nasdaq Stockholm.

Drugs giant AstraZeneca has listed on the New York Stock Exchange, as it targets further global growth.( Photo by Lynne Cameron/PA Wire)placeholder image
Drugs giant AstraZeneca has listed on the New York Stock Exchange, as it targets further global growth.( Photo by Lynne Cameron/PA Wire)

It told shareholders it hopes the new listing will help US investors to participate in the company’s “strong growth”.

AstraZeneca makes almost half of its revenues in the US and is targeting further growth in the world’s largest drugs market.

Last July, the company said it plans around $50bn (£36.5bn) in investment in the company by 2030.

It comes days after the group unveiled a tie-up with China’s CSPC Pharmaceutical Group to ramp up development of experimental weight loss and diabetes drugs in a deal worth $18.5bn (£13.4bn).

Under the deal, the FTSE 100 pharmaceutical giant will have access to the exclusive global rights, outside China, to CSPC’s once-a-month dose technology portfolio for weight management to offer more convenient solutions to daily injections.

Michel Demare, chairman of AstraZeneca, said: “Today marks the start of an exciting new period for AstraZeneca.”

Related topics:
News you can trust since 1754
Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice